Janssen Pharmaceutica Products LP has asked the Food and Drug Administration to approve a longer-acting version of Risperdal, its antipsychotic drug. Risperdal would be the first medication of its type available in a formulation suitable for long-term use and administration once every two …
The FDA has approved a 12.5-mg dose of Risperdal Consta for schizophrenia treatment. The product, marketed by Janssen LP, is also available in higher doses.
Most Popular
Top 10 Conflict Resolution and Communication Skills
Lethal Job Interview Mistakes
5 Super Tips To Get Rid Of Your Public Speaking Fear: How To Overcome Public Speaking Anxiety
Job Interview: What Not To Do
How To Write A Strategic Plan: A Simple Outline
…
FDA has given the go-ahead to AstraZenecas bipolar medication Seroquel XR and has sanctioned a new administration option for Janssens Risperdal, indicated for Schizophrenia.
Seroquel XR is the firs…
TITUSVILLE, N.J.–(BUSINESS WIRE)–Oct. 1, 1996–Risperdal(R) (risperidone), the drug therapy introduced by Janssen Pharmaceutica in 1994 for the management of psychotic disorders, has become the most often prescribed antipsychotic, capturing 20.7 percent of the market, the company announced today. New prescriptions written for Risperdal surpassed those…
The US Food and Drug Administration (FDA) has approved the use of Risperdal for treatment of two psychiatric disorders in children and adolescents.
Risperdal was approved to treat schizophrenia in 13-17 year olds and bipolar disorder in 10-17 year olds. Approval was granted after two six-eight week trials involving more than 500 children and adole…
Alkermes, Inc. (NASDAQ: ALKS) today announced positive preclinical
results for three proprietary molecules targeting opioid receptors,
including ALKS 33. Data from two preclinical studies demonstrated that
the three molecules showed statistically superior oral efficacy as
well as evidence for improved metabolic and pharmacokinetic profiles
compared to an active control. The data were presented at the 2008
Research Society on Alcoholism/International Soc…
Alkermes, Inc. (NASDAQ: ALKS) announced that it has received a
letter terminating the development and license agreement between Eli
Lilly and Company (Lilly) and Alkermes dated April 1, 2001 thereby
terminating the AIR(R) Inhaled Insulin (AIR(R) Insulin) program. The
termination will become effective in 90 days. The termination of the
agreement also results in the…
DUBLIN, Ireland — Research and Markets (http://www.researchandmarkets.com/reports/c64668) has announced the addition of “Johnson & Johnson: Performance, Products, Pipeline and Potential” to their offering.
Pharmaceutical company intelligence reports provide a full revie…
CAMBRIDGE, Mass. — Alkermes, Inc. (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live by Friedman, Billings, Ramsey & Co., Inc. on Wednesday, May 28, 2008 at 1:35 p.m. EDT. The presentation will be …
Heres a Big Pharma-and-FDA-are-going-steady story for the record books: While a growing number of states are suing Eli Lilly for hiding the fact that their antipsychotic drug Zyprexa causes obesity and diabetes in adult schizophrenia patients, a s…
